参考文献
关键文献
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: head and neck cancers [internet publication].全文
Amin MB, Edge SB, Greene FL, et al, eds. AJCC cancer staging manual. 8th ed. New York, NY: Springer International Publishing, 2017.
参考文献
1. El-Naggar AK, Chan JKC, Grandis JR, et al. eds. WHO classification of head and neck tumours. WHO classification of tumours, 4th ed. Vol 9. IARC Press; 2017.
2. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: head and neck cancers [internet publication].全文
3. Westra WH, Lewis JS Jr. Update from the 4th edition of the World Health Organization classification of head and neck tumours: oropharynx. Head Neck Pathol. 2017 Mar;11(1):41-7. 摘要
4. Badoual C. Update from the 5th edition of the World Health Organization classification of head and neck tumors: oropharynx and nasopharynx. Head Neck Pathol. 2022 Mar;16(1):19-30. 摘要
5. Mashiana SS, Navale P, Khandakar B, et al. Human papillomavirus genotype distribution in head and neck cancer: informing developing strategies for cancer prevention, diagnosis, treatment and surveillance. Oral Oncol. 2021 Feb;113:105109. 摘要
6. McIlwain WR, Sood AJ, Nguyen SA, et al. Initial symptoms in patients with HPV-positive and HPV-negative oropharyngeal cancer. JAMA Otolaryngol Head Neck Surg. 2014 May;140(5):441-7.全文 摘要
7. Liao CI, Francoeur AA, Kapp DS, et al. Trends in human papillomavirus-associated cancers, demographic characteristics, and vaccinations in the US, 2001-2017. JAMA Netw Open. 2022 Mar 1;5(3):e222530.全文 摘要
8. Centers for Disease Control and Prevention. HPV and oropharyngeal cancer. Sep 2023 [internet publication].全文
9. Mourad M, Jetmore T, Jategaonkar AA, et al. Epidemiological trends of head and neck cancer in the United States: A SEER population study. J Oral Maxillofac Surg. 2017 May 22;75(12):2562-72.全文 摘要
10. Ryerson AB, Peters ES, Coughlin SS, et al. Burden of potentially human papillomavirus-associated cancers of the oropharynx and oral cavity in the US, 1998-2003. Cancer. 2008 Nov 15;113(10 suppl):2901-9. 摘要
11. Gandini S, Botteri E, Iodice S, et al. Tobacco smoking and cancer: a meta-analysis. Int J Cancer. 2008 Jan 1;122(1):155-64.全文 摘要
12. Turati F, Garavello W, Tramacere I, et al. A meta-analysis of alcohol drinking and oral and pharyngeal cancers. Part 2: results by subsites. Oral Oncol. 2010 Oct;46(10):720-6. 摘要
13. Turati F, Garavello W, Tramacere I, et al. A meta-analysis of alcohol drinking and oral and pharyngeal cancers: results from subgroup analyses. Alcohol and Alcoholism. 2013 Jan-Feb;48(1):107-18.全文 摘要
14. Critchley JA, Unal B. Health effects associated with smokeless tobacco: a systematic review. Thorax. 2003 May;58(5):435-43.全文 摘要
15. Znaor A, Brennan P, Gajalakshmi V, et al. Independent and combined effects of tobacco smoking, chewing and alcohol drinking on the risk of oral, pharyngeal and esophageal cancers in Indian men. Int J Cancer. 2003 Jul 10;105(5):681-6.全文 摘要
16. D'Souza G, Kreimer AR, Viscidi R, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med. 2007 May 10;356(19):1944-56.全文 摘要
17. Suk R, Mahale P, Sonawane K, et al. Trends in risks for second primary cancers associated with index human papillomavirus-associated cancers. JAMA Netw Open. 2018 Sep 7;1(5):e181999.全文 摘要
18. Hecht SS. Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst. 1999 Jul 21;91(14):1194-210.全文 摘要
19. Baan R, Straif K, Grosse Y, et al. Carcinogenicity of alcoholic beverages. Lancet Oncol. 2007 Apr;8(4):292-3. 摘要
20. Hashibe M, Brennan P, Strange RC, et al. Meta- and pooled analyses of GSTM1, GSTT1, GSTP1, and CYP1A1 genotypes and risk of head and neck cancer. Cancer Epidemiol Biomarkers Prev. 2003 Dec;12(12):1509-17.全文 摘要
21. Wang X, Wang HK, McCoy JP, et al. Oncogenic HPV infection interrupts the expression of tumor-suppressive miR-34a through viral oncoprotein E6. RNA. 2009 Apr;15(4):637-47.全文 摘要
22. Boffetta P, Hecht S, Gray N, et al. Smokeless tobacco and cancer. Lancet Oncol. 2008 Jul;9(7):667-75. 摘要
23. Chen YJ, Chang JT, Liao CT, et al. Head and neck cancer in the betel quid chewing area: recent advances in molecular carcinogenesis. Cancer Sci. 2008 Aug;99(8):1507-14.全文 摘要
24. Chaturvedi AK, Engels EA, Anderson WF, et al. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol. 2008 Feb 1;26(4):612-9.全文 摘要
25. Hammarstedt L, Dahlstrand H, Lindquist D, et al. The incidence of tonsillar cancer in Sweden is increasing. Acta Otolaryngol. 2007 Sep;127(9):988-92. 摘要
26. Lee JJ, Jeng JH, Wang HM, et al. Univariate and multivariate analysis of prognostic significance of betel quid chewing in squamous cell carcinoma of buccal mucosa in Taiwan. J Surg Oncol. 2005 Jul 1;91(1):41-7. 摘要
27. Human papillomavirus vaccines: WHO position paper, December 2022. Wkly Epidemiol Rec. 2022 Dec 16;97(50):645-72.全文
29. Meites E, Szilagyi PG, Chesson HW, et al. Human papillomavirus vaccination for adults: updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2019 Aug 16;68(32):698-702.全文 摘要
30. Epstein JB, Gorsky M, Cabay RJ, et al. Screening for and diagnosis of oral premalignant lesions and oropharyngeal squamous cell carcinoma: role of primary care physicians. Can Fam Physician. 2008 Jun;54(6):870-5.全文 摘要
31. Nguyen NP, Vos P, Moltz CC, et al. Analysis of the factors influencing dysphagia severity upon diagnosis of head and neck cancer. Br J Radiol. 2008 Sep;81(969):706-10. 摘要
32. Nguyen NP, Vos P, Lee H, et al. Impact of tumor board recommendations on treatment outcome for locally advanced head and neck cancer. Oncology. 2008;75(3-4):186-91. 摘要
33. Nguyen NP, North D, Smith HJ, et al. Safety and effectiveness of prophylactic gastrostomy tubes for head and neck cancer patients undergoing chemoradiation. Surg Oncol. 2006 Dec;15(4):199-203. 摘要
34. Amin MB, Edge SB, Greene FL, et al, eds. AJCC cancer staging manual. 8th ed. New York, NY: Springer International Publishing, 2017.
35. Lenz M, Greess H, Baum U, et al. Oropharynx, oral cavity, floor of the mouth: CT or MRI. Eur J Radiol. 2000 Mar;33(3):203-15. 摘要
36. Zima AJ, Wesolowski JR, Ibrahim N, et al. Magnetic resonance imaging of oropharyngeal cancer. Top Magn Reson Imaging. 2007 Aug;18(4):237-42. 摘要
37. Wong RJ. Current status of FDG-PET for head and neck cancer. J Surg Oncol. 2008 Jun 15;97(8):649-52. 摘要
38. Branstetter BF 4th, Blodgett TM, Zimmer LA, et al. Head and neck malignancy: is PET/CT more accurate than PET or CT alone? Radiology. 2005 May;235(2):580-6. 摘要
39. Kim SJ, Pak K, Kim K. Diagnostic accuracy of F-18 FDG PET or PET/CT for detection of lymph node metastasis in clinically node negative head and neck cancer patients; A systematic review and meta-analysis. Am J Otolaryngol. 2019 Mar - Apr;40(2):297-305. 摘要
40. Heron DE, Andrade RS, Beriwal S, et al. PET-CT in radiation oncology: the impact on diagnosis, treatment planning, and assessment of treatment response. Am J Clin Oncol. 2008 Aug;31(4):352-62. 摘要
41. Balm AJ, van Velthuysen ML, Hoebers FJ, et al. Diagnosis and treatment of a neck node swelling suspicious for a malignancy: an algorithmic approach. Int J Surg Oncol. 2010 May 30;2010:581540.全文 摘要
42. van den Brekel MW, Casteljins JA, Stel HV, et al. Modern imaging techniques and ultrasound-guided aspiration cytology for the assessment of neck node metastases: a prospective comparative study. Eur Arch Otorhinolaryngol. 1993;250(1):11-7. 摘要
43. Dabirmoghaddam P, Sharifkashany S, Mashali L. Ultrasound-guided fine needle aspiration cytology in the assessment of cervical metastasis in patients undergoing elective neck dissection. Iran J Radiol. 2014 Aug;11(3):e7928. 摘要
44. Lewis JS Jr, Beadle B, Bishop JA, et al. Human papillomavirus testing in head and neck carcinomas: guideline from the college of American pathologists. Arch Pathol Lab Med. 2018 May;142(5):559-97.全文 摘要
45. Guardiola E, Pivot X, Dassonville O, et al. Is routine triple endoscopy for head and neck carcinoma patients necessary in light of a negative chest computed tomography scan? Cancer. 2004 Nov 1;101(9):2028-33.全文 摘要
46. Hujala K, Sipilä J, Grenman R. Panendoscopy and synchronous second primary tumors in head and neck cancer patients. Eur Arch Otorhinolaryngol. 2005 Jan;262(1):17-20. 摘要
47. Guardiola E, Chaigneau L, Villanueva C, et al. Is there still a role for triple endoscopy as part of staging for head and neck cancer? Curr Opin Otolaryngol Head Neck Surg. 2006 Apr;14(2):85-8. 摘要
48. Erdi YE. Limits of tumor detectability in nuclear medicine and PET. Mol Imaging Radionucl Ther. 2012 Apr 1;21(1):23-8.全文 摘要
49. Miller FR, Karnad AB, Eng T, et al. Management of the unknown primary carcinoma: long-term follow-up on a negative PET scan and negative panendoscopy. Head Neck. 2008 Jan;30(1):28-34.全文 摘要
50. Pitchers M, Martin C. Delay in referral of oropharyngeal squamous cell carcinoma to secondary care correlates with a more advanced stage at presentation, and is associated with poorer survival. Br J Cancer. 2006 Apr 10;94(7):955-8.全文 摘要
51. Roosli C, Tschudi DC, Studer G, et al. Outcome of patients after treatment for a squamous cell carcinoma of the oropharynx. Laryngoscope. 2009 Mar;119(3):534-40. 摘要
52. Koivunen P, Rantala N, Hyrynkangas, et al. The impact of patient and professional diagnostic delays on survival in pharyngeal cancer. Cancer. 2001 Dec 1;92(11):2885-91.全文 摘要
53. Tromp DM, Brouha XD, Hordijk GJ, et al. Patient and tumour factors associated with advanced carcinomas of the head and neck. Oral Oncol. 2005 Mar;41(3):313-9. 摘要
54. van Bokhorst-de van der Schueren MA, van Leeuwen PA, Sauerwein HP, et al. Assessment of malnutrition parameters in head and neck cancer and their relation to postoperative complications. Head Neck. 1997 Aug;19(5):419-25. 摘要
55. Ho T, Zahurak M, Koch WM. Prognostic significance of presentation-to-diagnosis interval in patients with oropharyngeal carcinoma. Arch Otolaryngol Head Neck Surg. 2004 Jan;130(1):45-51.全文 摘要
56. Ichimura K, Tanaka T. Trismus in patients with malignant tumours in the head and neck. J Laryngol Otol. 1993 Nov;107(11):1017-20. 摘要
57. Nahmias C, Lemmens C, Faul D, et al. Does reducing CT artifacts from dental implants influence the PET interpretation in PET/CT studies of oral cancer and head and neck cancer? J Nucl Med. 2008 Jul;49(7):1047-52.全文 摘要
58. Gourin CG, Watts T, Willams HT, et al. Identification of distant metastases with PET-CT in patients with suspected recurrent head and neck cancer. Laryngoscope. 2009 Apr;119(4):703-6. 摘要
59. Pantvaidya GH, Agarwal JP, Deshpande MS, et al. PET-CT in recurrent head neck cancers: a study to evaluate impact on patient management. J Surg Oncol. 2009 Oct 1;100(5):401-3. 摘要
60. Abgral R, Querellou S, Potard G, et al. Does 18-FDG PET/CT improve the detection of posttreatment recurrence of head and neck squamous cell carcinoma in patients negative for disease on clinical follow-up? J Nucl Med. 2009 Jan;50(1):24-9. 摘要
61. Connell CA, Corry J, Milner AD, et al. Clinical impact of, and prognostic stratification by, F-18 FDG PET/CT in head and neck mucosal squamous cell carcinoma. Head Neck. 2007 Nov;29(11):986-95. 摘要
62. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982 Dec;5(6):649-55. 摘要
63. Epstein JB, Silverman S Jr., Epstein JD, et al. Analysis of oral lesion biopsies identified and evaluated by visual examination, chemoluminescence and toluidine blue. Oral Oncol. 2008 Jun;44(6):538-44. [Erratum in: Oral Oncol. 2008 Jun;44(6):615.] 摘要
64. NIH National Cancer Institute. Oral cavity, pharyngeal, and laryngeal cancer screening (PDQ®) - health professional version. May 2023 [internet publication].全文
65. Cosmidis A, Rame JP, Dassonville O, et al; Groupement d'Etudes des Tumeurs de la Tête et du Cou (GETTEC). T1-T2 N0 oropharyngeal cancers treated with surgery alone: a GETTEC study. Eur Arch Otorhinolaryngol. 2004 May;261(5):276-81. 摘要
66. Parsons JT, Mendenhall WM, Stringer SP, et al. Squamous cell carcinoma of the oropharynx: surgery, radiotherapy, or both. Cancer. 2002 Jun 1;94(11):2967-80.全文 摘要
67. Soo KC, Tan EH, Wee J, et al. Surgery and adjuvant radiotherapy vs concurrent chemoradiotherapy in stage III/IV nonmetastatic squamous cell head and neck cancer: a randomised comparison. Br J Cancer. 2005 Aug 8;93(3):279-86.全文 摘要
68. Rieger J, Dickson N, Lemire R, et al. Social perception of speech in individuals with oropharyngeal reconstruction. J Psychosoc Oncol. 2006;24(4):33-51. 摘要
69. Rogers SN, Miller RD, Ali K, et al. Patients' perceived health status following primary surgery for oral and oropharyngeal cancer. Int J Oral Maxillofac Surg. 2006 Oct;35(10):913-9. 摘要
70. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006 Feb 9;354(6):567-78.全文 摘要
71. Xu Q, Huang S, Yang K. Combination immunochemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: a systematic review and meta-analysis. BMJ Open. 2023 Jun 13;13(6):e069047.全文 摘要
72. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008 Sep 11;359(11):1116-27.全文 摘要
73. Adelstein DJ, Ismaila N, Ku JA, et al. Role of treatment deintensification in the management of p16+ oropharyngeal cancer: ASCO provisional clinical opinion. J Clin Oncol. 2019 Jun 20;37(18):1578-89.全文 摘要
74. Nichols AC, Faquin WC, Westra WH, et al. HPV-16 infection predicts treatment outcome in oropharyngeal squamous cell carcinoma. Otolaryngol Head Neck Surg. 2009 Feb;140(2):228-34. 摘要
75. Lassen P, Eriksen JG, Hamilton-Dutoit S, et al. Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. J Clin Oncol. 2009 Apr 20;27(12):1992-8. 摘要
76. Fakhry C, Westra W, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst. 2008 Feb 20;100(4):261-9.全文 摘要
77. Parikh A, Lin D, Goyal N. Clinical outcomes of transoral robotic-assisted surgery for the management of head and neck cancer. Robot Surg. 2023 Feb 20;2(2015):95-105.全文
78. Denittis AS, Machtay M, Rosenthal DI, et al. Advanced oropharyngeal cancer treated with surgery and radiotherapy: oncologic outcome and functional assessment. Am J Otolaryngol. 2001 Sep-Oct;22(5):329-35. 摘要
79. Lim YC, Hong HJ, Baek SJ, et al. Combined surgery and postoperative radiotherapy for oropharyngeal squamous cell carcinoma in Korea: analysis of 110 cases. Int J Oral Maxillofac Surg. 2008 Dec;37(12):1099-105. 摘要
80. Nguyen NP, Vos P, Smith HJ, et al. Concurrent chemoradiation for locally advanced oropharyngeal cancer. Am J Otolaryngol. 2007 Jan-Feb;28(1):3-8. 摘要
81. Adelstein DJ, Saxton JP, Lavertu P, et al. A phase III randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and IV squamous cell head and neck cancer: preliminary results. Head Neck. 1997 Oct;19(7):567-75. 摘要
82. Blanchard P, Baujat B, Holostenco V, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site. Radiother Oncol. 2011 Jul;100(1):33-40. 摘要
83. Budach V, Stuschke M, Budach W, et al. Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the Radiotherapy Cooperative Clinical Trials Group of the German Cancer Society 95-06 Prospective Randomized Trial. J Clin Oncol. 2005 Feb 20;23(6):1125-35.全文 摘要
84. Tao Y, Auperin A, Sire C, et al. Improved outcome by adding concurrent chemotherapy to cetuximab and radiotherapy for locally advanced head and neck carcinomas: results of the GORTEC 2007-01 phase III randomized trial. J Clin Oncol. 2018 Nov;36(31):3084-90. 摘要
85. Gillison ML, Trotti AM, Harris J, et al. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. Lancet. 2018 Nov 15;393(10166):40-50. 摘要
86. Mehanna H, Robinson M, Hartley A, et al. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. Lancet. 2018 Nov 15;393(10166):51-60.全文 摘要
87. Bensadoun RJ, Benezery K, Dassonville O, et al. French multicenter phase III randomized study testing concurrent twice-a-day radiotherapy and cisplatin/5-fluorouracil chemotherapy (BiRCF) in unresectable pharyngeal carcinoma: results at 2 years (FNCLCC-GORTEC). Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):983-94. 摘要
88. Staar S, Rudat V, Stuetzer H, et al. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy: results of a multicentric randomized German trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1161-71. [Erratum in: Int J Radiat Oncol Biol Phys 2001 Oct 1;51(2):569.] 摘要
89. Semrau R, Mueller RP, Stuetzer H, et al. Efficacy of intensified hyperfractionated and accelerated radiotherapy and concurrent chemotherapy with carboplatin and 5-fluorouracil: updated results of a randomized multicentric trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2006 Apr 1;64(5):1308-16. 摘要
90. Denis F, Garaud P, Bardet E, et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant chemoradiotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol. 2004 Jan 1;22(1):69-76.全文 摘要
91. Calais G, Alfonsi M, Bardet E, et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst. 1999 Dec 15;91(24):2081-6.全文 摘要
92. Brizel DM, Albers ME, Fisher SR, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med. 1998 Jun 18;338(25):1798-804.全文 摘要
93. Pignon JP, le Maitre A, Maillard E, et al; MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009 Jul;92(1):4-14. 摘要
94. Posner MR, Hershock DM, Blajman CR, et al; TAX 324 Study Group. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007 Oct 25;357(17):1705-15.全文 摘要
95. Adelstein DJ, Li Y, Adams GL, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol. 2003 Jan 1;21(1):92-8. 摘要
96. Blanchard P, Bourhis J, Lacas B, et al; Meta-Analysis of Chemotherapy in Head and Neck Cancer, Induction Project, Collaborative Group. Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group. J Clin Oncol. 2013 Aug 10;31(23):2854-60.全文 摘要
97. Martins RG, Parvathaneni U, Bauman JE, et al. Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial. J Clin Oncol. 2013 Apr 10;31(11):1415-21.全文 摘要
98. Mesia R, Henke M, Fortin A, et al. Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial. Lancet Oncol. 2015 Feb;16(2):208-20. 摘要
99. Burtness B, Goldwasser MA, Flood W, et al. A phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol. 2005 Dec 1;23(34):8646-54. [Erratum in: J Clin Oncol. 2006 Feb 1;24(4):724.]全文 摘要
100. Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med. 2009 Feb 5;360(6):563-72.全文 摘要
101. Bumpous JM. Surgical salvage of cancer of the oropharynx after chemoradiation. Curr Oncol Rep. 2009 Mar;11(2):151-5. 摘要
102. Watkins JM, Shirai KS, Wahlquist AE, et al. Toxicity and survival outcomes of hyperfractionated split-course reirradiation and daily concurrent chemotherapy in locoregionally recurrent, previously irradiated head and neck cancers. Head Neck. 2009 Apr;31(4):493-502. 摘要
103. Seiwert TY, Burtness B, Mehra R, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 2016 May 27;17(7):956-65. 摘要
104. Chow LQ, Haddad R, Gupta S, et al. Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort. J Clin Oncol. 2016 Sep 30;34(32):3838-45.全文 摘要
105. Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019 Nov 23;394(10212):1915-28. 摘要
106. National Institute for Health and Care Excellence. Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma. Nov 2020 [internet publication].全文
107. Ferris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016 Nov 10;375(19):1856-67.全文 摘要
108. Harrington KJ, Ferris RL, Blumenschein G Jr, et al. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. Lancet Oncol. 2017 Aug;18(8):1104-15. 摘要
109. National Institute for Health and Care Excellence. Nivolumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy. Oct 2021 [internet publication].全文
110. Seiwert TY, Burtness B, Mehra R, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 2016 May 27;17(7):956-65. 摘要
111. Brock PR, Maibach R, Childs M, et al. Sodium thiosulfate for protection from cisplatin-induced hearing loss. N Engl J Med. 2018 Jun 21;378(25):2376-85.全文 摘要
112. Meluch AA, Spigel D, Burris HA, et al. Combined modality therapy with radiation therapy (RT), chemotherapy, bevacizumab, and erlotinib in the treatment of patients (pts) with locally advanced squamous carcinoma of the head and neck. J Clin Oncol. 2009 May 20;27(15_suppl):6012.
113. Mercke C, Wickart-Johansson G, Sjodin H, et al. Upfront chemotherapy and accelerated radiotherapy with EGFR inhibition for locally advanced inoperable head and neck cancer. J Clin Oncol. 2009 May 20;27(15_suppl):6040.
114. Vermorken JB, Stöhlmacher-Williams J, Davidenko I, et al; SPECTRUM investigators. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. Lancet Oncol. 2013 Jul;14(8):697-710. 摘要
115. Pang E, Delic NC, Hong A, et al. Radiosensitization of oropharyngeal squamous cell carcinoma cells by human papillomavirus 16 oncoprotein E6∗I. Int J Radiat Oncol Biol Phys. 2011 Mar 1;79(3):860-5. 摘要
116. Young R, Rischin D, Fisher R, et al. Relationship between epidermal growth factor receptor status, p16(INK4A), and outcome in head and neck squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev. 2011 Jun;20(6):1230-7. 摘要
117. Nguyen NP, Ceizyk M, Vos P, et al. Feasibility of tomotherapy-based image-guided radiotherapy for locally advanced oropharyngeal cancer. PLoS One. 2013;8(3):e60268.全文 摘要
118. Rischin D, Young RJ, Fisher R, et al. Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol. 2010 Sep 20;28(27):4142-8. 摘要
119. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010 Jul 1;363(1):24-35.全文 摘要
120. Nguyen NP, Ly BH, Betz M, et al. Importance of age as a prognostic factor fortonsillar carcinoma. Ann Surg Oncol. 2010 Oct;17(10):2570-7. 摘要
121. Le Scodan R, Pommier P, Ardiet JM, et al. Exclusive brachytherapy for T1 and T2 squamous cell carcinomas of the velotonsillar area: results in 44 patients. Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):441-8. 摘要
122. Levendag P, Nijdam W, Noever I, et al. Brachytherapy versus surgery in carcinoma of tonsillar fossa and/or soft palate: late adverse sequelae and performance status: can we be more selective and obtain better tissue sparing? Int J Radiat Oncol Biol Phys. 2004 Jul 1;59(3):713-24. 摘要
123. Bernier J, Domenge C, Ozsahin M, et al; European Organization for Research and Treatment of Cancer Trial 22931. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004 May 6;350(19):1945-52.全文 摘要
124. Guha S, Kelly CG, Guha R, et al. Intensity modulated radiation therapy (IMRT) in the treatment of squamous carcinoma of the oropharynx: an overview. J Cancer Sci Ther. 2012;4(4):77-83.全文
125. Grønhøj C, Jensen JS, Wagner S, et al. Impact on survival of tobacco smoking for cases with oropharyngeal squamous cell carcinoma and known human papillomavirus and p16-status: a multicenter retrospective study. Oncotarget. 2019 Jul 23;10(45):4655-63.全文 摘要
126. Elhalawani H, Mohamed ASR, Elgohari B, et al. Tobacco exposure as a major modifier of oncologic outcomes in human papillomavirus (HPV) associated oropharyngeal squamous cell carcinoma. BMC Cancer. 2020 Sep 23;20(1):912.全文 摘要
127. McCombe D, Lyons B, Winkler R, et al. Speech and swallowing following radial forearm flap reconstruction of major soft palate defect. Br J Plast Surg. 2005 Apr;58(3):306-11. 摘要
128. Gillespie MB, Eisele DW. The uvulopalatal flap for reconstruction of the soft palate. Laryngoscope. 2000 Apr;110(4):612-5. 摘要
129. Erkal HS, Serin M, Amdur RJ, et al. Squamous cell carcinoma of soft palate treated with radiation therapy alone or followed by planned neck dissection. Int J Radiat Oncol Biol Phys. 2001 Jun 1;50(2):359-66. 摘要
130. Kazi R, Prasad VM, Kanagalingam J, et al. Analysis of formant frequencies in patients with oral and oropharyngeal cancers treated by glossectomy. Int J Lang Commun Disord. 2007 Sep-Oct;42(5):521-32. 摘要
131. Harrison LB, Zelefsky MJ, Armstrong JG, et al. Performance status after treatment for squamous cell cancer of the base of tongue: a comparison of primary radiation therapy versus primary surgery. Int J Radiat Oncol Biol Phys. 1994 Nov 15;30(4):953-7. 摘要
132. Nguyen NP, Moltz CC, Frank C, et al. Effectiveness of the cough reflex in patients with aspiration following radiation for head and neck cancer. Lung. 2007 Sep-Oct;185(5):243-8. 摘要
133. Kam MK, Leung SF, Zee B, et al. Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early stage nasopharyngeal carcinoma patients. J Clin Oncol. 2007 Nov 1;25(31):4873-9.全文 摘要
134. Helson L, Okonkwo E, Anton L, et al. cis-Platinum ototoxicity. Clin Toxicol. 1978;13(4):469-78. 摘要
135. Bokemeyer C, Berger CC, Hartmann JT, et al. Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. Br J Cancer. 1998 Apr;77(8):1355-62.全文 摘要
136. Melamed LB, Selim MA, Schuchman D. Cisplatin ototoxicity in gynecologic cancer patients. A preliminary report. Cancer. 1985 Jan 1;55(1):41-3. 摘要
137. Hitchcock YJ, Tward JD, Szabo A, et al. Relative contributions of radiation and cisplatin-based chemotherapy to sensorineural hearing loss in head-and-neck cancer patients. Int J Radiat Oncol Biol Phys. 2009 Mar 1;73(3):779-88. 摘要
138. Jereczek-Fossa BA, Zarowski A, Milani F, et al. Radiotherapy-induced ear toxicity. Cancer Treat Rev. 2003 Oct;29(5):417-30. 摘要
内容使用需遵循免责声明